Yoshioka Lab／BIKEN Innovative Vaccine Research Alliance Laboratories Vaccine Creation Group
Most protein antigens such as non-living macromolecules or protein-subunit antigens evoke weak or undetectable adaptive immune responses. Therefore, to develop effective vaccines it is necessary to develop vaccine adjuvants and antigen delivery carriers. In addition, to develop optimal (in terms of efficacy and safety) vaccines for clinical application, it is important to understand the mechanism by which vaccines act on the immune system. In this regard, our research is focused on optimizing vaccines through drug delivery systems and safety science. Our specific research projects are:
1) Development of vaccine adjuvants using comprehensive screening methods.
2) Development of antigen delivery carriers and adjuvants using nanotechnology.
3) To use these adjuvants and delivery carriers to develop vaccines for infectious diseases.
- SA Prof. : Yasuo Yoshioka (concur.)
- SA Assoc. Prof.: Toshiro Hirai (concur.)
- (1) Murine cross-reactive non-neutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice. Shibuya M et al. J Virol.(2020) pii: JVI.00323-20.
(2) Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides. Takahashi H, et al., Front Immunol. (2018) Apr 18;9:783.
(3) Distribution of silver nanoparticles to breast milk and their biological effects on breast-fed offspring mice. Morishita Y, Yoshioka Y, et al., ACS Nano. (2016) Aug 15.
(4) Metal nanoparticles in the presence of lipopolysaccharides trigger the onset of metal allergy in mice. Hirai T, Yoshioka Y, et al., Nat Nanotechnol. (2016) 11(9):808-16.
(5) Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Yamashita K, Yoshioka Y, et al., Nat Nanotechnol. (2011) 6(5):321-8.